METTL5 and Parkinson disease: Acting on a Heme group of donors with Heme-copper terminal oxidase activity (Fig. 10C), METTL5 were proven to largely participate in the signaling pathways of ribosome, oxidative phosphorylation, spliceosome, Parkinson disease, proteasome, and Huntington disease (Fig. 10D).